{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T18:17:25Z","timestamp":1779905845279,"version":"3.53.1"},"reference-count":41,"publisher":"The Endocrine Society","issue":"9","license":[{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U2C-DK119886"],"award-info":[{"award-number":["U2C-DK119886"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Glucagon is produced and released from the pancreatic alpha-cell to regulate glucose levels during periods of fasting. The main target for glucagon action is the liver, where it activates gluconeogenesis and glycogen breakdown; however, glucagon is postulated to have other roles within the body.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>We sought to identify the circulating metabolites that would serve as markers of glucagon action in humans.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this study (NCT03139305), we performed a continuous 72-hour glucagon infusion in healthy individuals with overweight\/obesity. Participants were randomized to receive glucagon 12.5 ng\/kg\/min (GCG 12.5), glucagon 25 ng\/kg\/min (GCG 25), or a placebo control. A comprehensive metabolomics analysis was then performed from plasma isolated at several time points during the infusion to identify markers of glucagon activity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Glucagon (GCG 12.5 and GCG 25) resulted in significant changes in the plasma metabolome as soon as 4 hours following infusion. Pathways involved in amino acid metabolism were among the most affected. Rapid and sustained reduction of a broad panel of amino acids was observed. Additionally, time-dependent changes in free fatty acids and diacylglycerol and triglyceride species were observed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>These results define a distinct signature of glucagon action that is broader than the known changes in glucose levels. In particular, the robust changes in amino acid levels may prove useful to monitor changes induced by glucagon in the context of additional glucagon-like peptide-1 or gastric inhibitory polypeptide treatment, as these agents also elicit changes in glucose levels.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jendso\/bvab118","type":"journal-article","created":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T19:22:48Z","timestamp":1624648968000},"source":"Crossref","is-referenced-by-count":20,"title":["A Metabolomic Signature of Glucagon Action in Healthy Individuals With Overweight\/Obesity"],"prefix":"10.1210","volume":"5","author":[{"given":"Rick B","family":"Vega","sequence":"first","affiliation":[{"name":"Translational Research Institute, AdventHealth, Orlando, FL 32804, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3486-9452","authenticated-orcid":false,"given":"Katie L","family":"Whytock","sequence":"additional","affiliation":[{"name":"Translational Research Institute, AdventHealth, Orlando, FL 32804, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Gassenhuber","sequence":"additional","affiliation":[{"name":"Sanofi R&D, 65926 Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Goebel","sequence":"additional","affiliation":[{"name":"Sanofi R&D, 65926 Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Tillner","sequence":"additional","affiliation":[{"name":"Sanofi R&D, 65926 Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inoncent","family":"Agueusop","sequence":"additional","affiliation":[{"name":"Sanofi R&D, 65926 Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka D","family":"Truax","sequence":"additional","affiliation":[{"name":"Metabolon, Morrisville, NC 27560, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gongxin","family":"Yu","sequence":"additional","affiliation":[{"name":"Translational Research Institute, AdventHealth, Orlando, FL 32804, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvis","family":"Carnero","sequence":"additional","affiliation":[{"name":"Translational Research Institute, AdventHealth, Orlando, FL 32804, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhi","family":"Kapoor","sequence":"additional","affiliation":[{"name":"Translational Research Institute, AdventHealth, Orlando, FL 32804, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Gardell","sequence":"additional","affiliation":[{"name":"Translational Research Institute, AdventHealth, Orlando, FL 32804, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren M","family":"Sparks","sequence":"additional","affiliation":[{"name":"Translational Research Institute, AdventHealth, Orlando, FL 32804, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5098-8147","authenticated-orcid":false,"given":"Steven R","family":"Smith","sequence":"additional","affiliation":[{"name":"Translational Research Institute, AdventHealth, Orlando, FL 32804, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2021,6,25]]},"reference":[{"issue":"Suppl 1)","key":"2021110514391521900_CIT0001","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1463-1326.2011.01454.x","article-title":"Physiologic action of glucagon on liver glucose metabolism","volume":"13","author":"Ramnanan","year":"2011","journal-title":"Diabetes Obes Metab."},{"issue":"5","key":"2021110514391521900_CIT0002","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.2337\/diabetes.48.5.1198","article-title":"Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo","volume":"48","author":"Cherrington","year":"1999","journal-title":"Diabetes."},{"issue":"2","key":"2021110514391521900_CIT0003","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2337\/diab.44.2.185","article-title":"Contribution of hepatic glycogenolysis to glucose production in humans in response to a physiological increase in plasma glucagon concentration","volume":"44","author":"Magnusson","year":"1995","journal-title":"Diabetes."},{"issue":"3","key":"2021110514391521900_CIT0004","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nrm3072","article-title":"CREB and the CRTC co-activators: sensors for hormonal and metabolic signals","volume":"12","author":"Altarejos","year":"2011","journal-title":"Nat Rev Mol Cell Biol."},{"issue":"1","key":"2021110514391521900_CIT0005","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1210\/jcem-64-1-106","article-title":"Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus","volume":"64","author":"Reaven","year":"1987","journal-title":"J Clin Endocrinol Metab."},{"issue":"11","key":"2021110514391521900_CIT0006","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.2337\/db16-0240","article-title":"Insulin resistance is accompanied by increased fasting glucagon and delayed glucagon suppression in individuals with normal and impaired glucose regulation","volume":"65","author":"F\u00e6rch","year":"2016","journal-title":"Diabetes."},{"issue":"5","key":"2021110514391521900_CIT0007","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1172\/JCI108188","article-title":"Effect of insulin-glucose infusions on plasma glucagon levels in fasting diabetics and nondiabetics","volume":"56","author":"Raskin","year":"1975","journal-title":"J Clin Invest."},{"issue":"19","key":"2021110514391521900_CIT0008","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.1016\/j.bmcl.2015.07.092","article-title":"Recent progress in the development of small-molecule glucagon receptor antagonists","volume":"25","author":"Sammons","year":"2015","journal-title":"Bioorg Med Chem Lett."},{"issue":"11","key":"2021110514391521900_CIT0009","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.2337\/db14-0242","article-title":"Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake","volume":"63","author":"Cegla","year":"2014","journal-title":"Diabetes."},{"issue":"4","key":"2021110514391521900_CIT0010","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2337\/db12-0797","article-title":"Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia","volume":"62","author":"Tan","year":"2013","journal-title":"Diabetes."},{"issue":"1 Pt 2","key":"2021110514391521900_CIT0011","first-page":"R116","article-title":"Glucagon acts in the liver to control spontaneous meal size in rats","volume":"264","author":"Geary","year":"1993","journal-title":"Am J Physiol."},{"issue":"3","key":"2021110514391521900_CIT0012","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1152\/jappl.1957.11.3.419","article-title":"Effect of glucagon on food intake and body weight in man","volume":"11","author":"Schulman","year":"1957","journal-title":"J Appl Physiol."},{"issue":"6","key":"2021110514391521900_CIT0013","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/oby.23141","article-title":"Prolonged glucagon infusion does not affect energy expenditure in individuals with overweight\/obesity: a randomized trial","volume":"29","author":"Whytock","year":"2021","journal-title":"Obesity."},{"issue":"4","key":"2021110514391521900_CIT0014","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/ng.3809","article-title":"Whole-genome sequencing identifies common-to-rare variants associated with human blood metabolites","volume":"49","author":"Long","year":"2017","journal-title":"Nat Genet."},{"issue":"1","key":"2021110514391521900_CIT0015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1758-2946-2-9","article-title":"Organization of GC\/MS and LC\/MS metabolomics data into chemical libraries","volume":"2","author":"Dehaven","year":"2010","journal-title":"J Cheminform."},{"key":"2021110514391521900_CIT0016","first-page":"297","article-title":"Metabolomics analyses of muscle atrophy induced by hind limb unloading","volume-title":"Methods Mol Biol","author":"Gardell","year":"2019"},{"issue":"3","key":"2021110514391521900_CIT0017","first-page":"765","article-title":"A paradigm of experimentally induced mild hyperthyroidism: effects on nitrogen balance, body composition, and energy expenditure in healthy young men","volume":"82","author":"Lovejoy","year":"1997","journal-title":"J Clin Endocrinol Metab."},{"issue":"7","key":"2021110514391521900_CIT0018","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"2021110514391521900_CIT0019","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/nar\/28.1.27","article-title":"KEGG: kyoto encyclopedia of genes and genomes","volume":"28","author":"Kanehisa","year":"2000","journal-title":"Nucleic Acids Res."},{"issue":"6","key":"2021110514391521900_CIT0020","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1021\/ci034160g","article-title":"Random forest: a classification and regression tool for compound classification and QSAR modeling","volume":"43","author":"Svetnik","year":"2003","journal-title":"J Chem Inf Comput Sci."},{"issue":"3","key":"2021110514391521900_CIT0021","first-page":"18","article-title":"Classification and regression by randomForest","volume":"2","author":"Liaw","year":"2002","journal-title":"R News"},{"key":"2021110514391521900_CIT0022","author":"Vega","year":"2021"},{"key":"2021110514391521900_CIT0023","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3389\/fphys.2019.00413","article-title":"Glucagon receptor signaling and lipid metabolism","volume":"10","author":"Galsgaard","year":"2019","journal-title":"Front Physiol."},{"issue":"1 Pt 1","key":"2021110514391521900_CIT0024","first-page":"E78","article-title":"Plasma amino acid kinetics during acute states of glucagon deficiency and excess in healthy adults","volume":"258","author":"Couet","year":"1990","journal-title":"Am J Physiol."},{"issue":"3","key":"2021110514391521900_CIT0025","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1172\/JCI111272","article-title":"Effects of glucagon on plasma amino acids","volume":"73","author":"Boden","year":"1984","journal-title":"J Clin Invest."},{"issue":"12","key":"2021110514391521900_CIT0026","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/0026-0495(81)90041-X","article-title":"Effects of pharmacologic hyperglucagonemia on plasma amino acid concentrations in normal and diabetic man","volume":"30","author":"Liljenquist","year":"1981","journal-title":"Metabolism."},{"issue":"4","key":"2021110514391521900_CIT0027","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0026-0495(69)90047-X","article-title":"Effect of glucagon on concentration of several free amino acids in plasma","volume":"18","author":"Landau","year":"1969","journal-title":"Metabolism."},{"issue":"1","key":"2021110514391521900_CIT0028","doi-asserted-by":"crossref","first-page":"E93","DOI":"10.1152\/ajpendo.00198.2017","article-title":"Disruption of glucagon receptor signaling causes hyperaminoacidemia exposing a possible liver-alpha-cell axis","volume":"314","author":"Galsgaard","year":"2018","journal-title":"Am J Physiol Endocrinol Metab."},{"issue":"3","key":"2021110514391521900_CIT0029","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.celrep.2015.06.034","article-title":"Glucagon couples hepatic amino acid catabolism to mtor-dependent regulation of \u03b1-cell mass","volume":"12","author":"Solloway","year":"2015","journal-title":"Cell Rep."},{"key":"2021110514391521900_CIT0030","doi-asserted-by":"crossref","first-page":"101080","DOI":"10.1016\/j.molmet.2020.101080","article-title":"Glucagon acutely regulates hepatic amino acid catabolism and the effect may be disturbed by steatosis","volume":"42","author":"Winther-S\u00f8rensen","year":"2020","journal-title":"Mol Metab."},{"issue":"5","key":"2021110514391521900_CIT0031","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.cmet.2008.09.008","article-title":"The glucagon receptor is required for the adaptive metabolic response to fasting","volume":"8","author":"Longuet","year":"2008","journal-title":"Cell Metab."},{"issue":"2","key":"2021110514391521900_CIT0032","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0005-2760(88)90283-4","article-title":"Effects of chronic glucagon administration on cholesterol and bile acid metabolism","volume":"963","author":"Guettet","year":"1988","journal-title":"Biochim Biophys Acta."},{"issue":"2","key":"2021110514391521900_CIT0033","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2337\/db10-0763","article-title":"Effects of acute hyperglucagonemia on hepatic and intestinal lipoprotein production and clearance in healthy humans","volume":"60","author":"Xiao","year":"2011","journal-title":"Diabetes."},{"issue":"11","key":"2021110514391521900_CIT0034","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1111\/dom.13440","article-title":"Efficacy and safety of the glucagon receptor antagonist PF-06291874: A 12-week, randomized, dose-response study in patients with type 2 diabetes mellitus on background metformin therapy","volume":"20","author":"Kazierad","year":"2018","journal-title":"Diabetes Obes Metab."},{"issue":"7","key":"2021110514391521900_CIT0035","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.2337\/dc15-1643","article-title":"Evaluation of efficacy and safety of the glucagon receptor antagonist ly2409021 in patients with type 2 diabetes: 12- and 24-week phase 2 studies","volume":"39","author":"Kazda","year":"2016","journal-title":"Diabetes Care."},{"issue":"11","key":"2021110514391521900_CIT0036","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/dom.12958","article-title":"Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes","volume":"19","author":"Guzman","year":"2017","journal-title":"Diabetes Obes Metab."},{"issue":"8","key":"2021110514391521900_CIT0037","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.2337\/diabetes.54.8.2390","article-title":"Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial","volume":"54","author":"Wynne","year":"2005","journal-title":"Diabetes."},{"issue":"10","key":"2021110514391521900_CIT0038","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1210\/jc.2003-030421","article-title":"Oxyntomodulin suppresses appetite and reduces food intake in humans","volume":"88","author":"Cohen","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"issue":"12","key":"2021110514391521900_CIT0039","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/dom.12735","article-title":"Robust anti-obesity and metabolic effects of a dual GLP-1\/glucagon receptor peptide agonist in rodents and non-human primates","volume":"18","author":"Henderson","year":"2016","journal-title":"Diabetes Obes Metab."},{"issue":"10140","key":"2021110514391521900_CIT0040","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1016\/S0140-6736(18)30726-8","article-title":"MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study","volume":"391","author":"Ambery","year":"2018","journal-title":"Lancet."},{"issue":"1","key":"2021110514391521900_CIT0041","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/dom.13494","article-title":"A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: results of randomized, placebo-controlled first-in-human and first-in-patient trials","volume":"21","author":"Tillner","year":"2019","journal-title":"Diabetes Obes Metab."}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jes\/advance-article-pdf\/doi\/10.1210\/jendso\/bvab118\/38826537\/bvab118.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/5\/9\/bvab118\/41090574\/bvab118.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/5\/9\/bvab118\/41090574\/bvab118.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T14:40:08Z","timestamp":1636123208000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvab118\/6309634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,25]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvab118","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9,1]]},"published":{"date-parts":[[2021,6,25]]},"article-number":"bvab118"}}